© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HER2-Positive Breast Cancer
Activity With Tucatinib Across the Blood-Brain Barrier Presents a Vital Option in HER2+ Breast Cancer
May 19, 2020
In an interview with Targeted Oncology, Rashmi Murthy, MD, discussed the final results from the HER2CLIMB study and the future of tucatinib as it makes its way to the community setting as treatment of advanced HER2--positive breast cancer.
Pertuzumab Added to Trastuzumab and Chemotherapy Improves Survival in HER2+ Breast Cancer
May 09, 2020
"HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%."
TCbHP/T-DM1+P Sequence Shows Promise in HER2+ Primary Breast Cancer
May 04, 2020
A new phase II trial showed higher pathological complete response rates in patients with HER2-positive breast cancer who took docetaxel, carboplatin, trastuzumab, and pertuzumab followed by trastuzumab emtansine, and pertuzumab, versus those who took only the former therapy.
Survival Improved With the Addition of Chemotherapy for Small HER2-Positive Breast Cancer
April 23, 2020
"We know that, in general, patients with this particular subset of hormone-receptor-positive breast cancers should get chemotherapy, but all the studies showing the benefits of chemotherapy included patients with large cancers."
Talazoparib Toxicities Manageable in gBRCA-Mutated HER2-Negative Advanced Breast Cancer
April 20, 2020
Safety data from the phase III EMBRACA trial were recently published. Talazoparib appears to be safe with manageable toxicities in patients with germline BRCA-mutated HER2-negative advanced breast cancer.
Systemic Therapies Shown to be Effective in HER2-Positive Breast Cancer
April 20, 2020
Nancy Lin, MD, discusses options for patients with human epidermal growth factor receptor 2-positive breast cancer who also present with brain metastases.
Women With Indigenous American Ancestry Have Higher Odds of HER2-Positive Breast Cancer
April 08, 2020
Indigenous American ancestry has been linked to an increased incidence of HER2-positive breast cancer, according to the Peruvian Genetics and Genomics of Breast Cancer Study study published in Cancer Research.
Platinum Chemotherapy Nonsuperior to Standard Chemotherapy in HER2-Negative Breast Cancer
March 07, 2020
Despite evidence from previous studies that showed that platinum-based chemotherapy agents are active in patients with breast cancer, platinum-based chemotherapy was not found to be superior to standard chemotherapy in terms of eliciting pathologic complete responses in patients with HER2-negative breast cancer carrying a BRCA mutation, according to data from the INFORM trial published in the Journal of Clinical Oncology.
The Rationale for the Phase I TRANSCEND NHL 001 Trial
February 13, 2020
Exploring Potential HER2-Positive Breast Cancer Treatments for the Future
January 29, 2020
Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.